Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (September 2016)
21 slides from Sorrento Therapeutics's investor presentation, September 2016
Slide 1: Sorrento Therapeutics - OnTarget, September 2016
Therapeutics OnTarget September - 2016 (c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved.
Slide 2: Disclaimer
Disclaimer NASDAQ: SRNE Certain statements contained in this presentation or in other documents of In presenting this material or responding to inquiries in connection with a Sorrento Therapeutics, Inc. (the “Company”), along with certain statements presentation, management may refer to results, pro
Slide 3: Presentation Summary
Presentation Summary Company History Core Technologies & Platforms Sorrento Therapeutics Structure Programs and Pipeline Status Partnerships Recent News & Financial Summary Conclusion (c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved. 3
Slide 4: Company History
Company History 2006 - Founded 2009 - Funding and commencement of operations 2010 - G-MAB Library 2013 - NASDAQ Listing, Development and Asset Acquisitions - Cynviloq, RTX & ADC 2014 - License deals with “NANT” companies 2015 - Asset Acquisitions - CAR-T, BioSimilars, Intracellular 2016 - $150M PIPE
Slide 5: Core Technologies - Antibody Therapeutics - G-MAB Library
Core Technologies - Antibody Therapeutics - G-MAB Library Highly Successful Fully Human Antibodies Screening Hit Rate (100+ targets screened) Proprietary Technology Very High Diversity RNA amplification used for library generation 2.1 x 10 16 Distinct Antibodies Difficult Targets High Value Oncology
Slide 6: Core Technologies - Antibody Therapeutics - G-MAB Library
Core Technologies - Antibody Therapeutics - G-MAB Library G-MAB library: Bispecific Antibodies: • One of the largest fully human antibody libraries • Targeting two different receptors in • More than 10 quadrillion (1016) distinct antibody combination on the same cell sequences • Over 100 clinically-
Slide 7: Core Technologies - Multi-Faceted Immunotherapy Platform
Core Technologies - Multi-Faceted Immunotherapy Platform ADCs Antibody Drug Conjugates Proprietary Toxins Intracellular c-MET Conjugation Chemistries Targets Adoptive Immunotherapy PD-L1 Secreted BispecificAbs Targets CAR-T PD-1 CAR.NK (c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved. Immuno
Slide 8: Sorrento Therapeutics Structure
Sorrento Therapeutics Structure Pain Management Scintilla (c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved. 8
Slide 9: Programs – Sorrento Biologics - Biosimilar/Biobetters (mAbs)
Programs – Sorrento Biologics- Biosimilar /Biobetters (mAbs) Sorrento Biologics Program Summary: • Exclusive licensing agreement with Mabtech Limited to develop and commercialize biosimilar antibodies, 4 to date: • Erbitux® (STI-001, cetuximab), • Remicade® (STI-002, infliximab), • Simulect® (STI-00
Slide 10: Programs – Sorrento Biologics - Significant Commercial Opportunities
Programs – Sorrento Biologics- Biosimilar /Biobetters (mAbs) Significant Commercial Opportunities Product Generic Target Brand 2014 Global • Targeting $12 B+ market Sales (US$) STI-001 Cetuximab EGFR Erbitux $1.9B • Significant opportunities for STI-002 Infliximab TNFα Remicade $0.9B combination the
Slide 11: Programs - CAR-T & CAR-pNK - TNK Therapeutics
Programs - CAR-T & CAR-pNK - TNK Therapeutics Chimeric Antigen Receptor (CAR) Based Immunotherapies Program Summary: • Autologous and allogeneic CAR-T and CAR.NK therapies • Leading autologous clinical candidates in development are: • T-001 (Anti-CEA CAR-T) • T-002 (Anti-PSMA CAR-T) • T-007 (Anti-CD
Slide 12: Programs - LA Cell - Cell-Penetrating Antibody Delivery
Programs - LA Cell - Cell-Penetrating Antibody Delivery Novel Breakthrough Intracellular Targeting Antibody -iTab™ • Modulation of intracellular targets with antibody therapeutics will greatly increase druggable space • Specific modification of antibodies enables efficient cellular internalization,
Slide 13: Programs - LA Cell – iTAb Discovery Platform
Programs - LA Cell – iTAb Discovery Platform Basic Research – Full Discovery – Collaborations with Large Pharma Exploratory Antibody Antibody Functionality Developability In Vivo PK/PD and Tox Study Panning Modification Evaluation Assessment Biodistribution Efficacy Study (c) 2016 Sorrento Therapeut
Slide 14: Programs – Antibody-Drug Conjugates – Concortis
Programs – Antibody-Drug Conjugates – Concortis Next Generation Antibody-Drug Conjugates • Cytotoxic drugs conjugated to antibodies via chemical linkers • Site-specific conjugation methods to provide homogenous products: • K-Lock™ & C-Lock™ • Proprietary Toxins: tublin-binding, DNA alkylation & othe
Slide 15: Programs – Pain Management – Scintilla Pharmaceuticals
Programs – Pain Management – Scintilla Pharmaceuticals Scintilla Pharmaceuticals –Subsidiary Focused on Pain Management RTX (resiniferatoxin) • Non-opioid-based pain treatment that selectively binds to the TRPV-1 receptor and creates an ultra-potent agonist signal that leads to calcium influx induce
Slide 16: Partnerships – Global Immuno-Oncology Partners
Partnerships – Global Immuno-Oncology Partners Laboratoires Servier Servier, the largest non-listed pharmaceutical company in France, announced a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento's fully human immuno-oncology anti-P
Slide 17: Partnerships – Global Cellular Therapy and ADC Partners
Partnerships – Global Cellular Therapy and ADC Partners 3SBio TNK Therapeutics has an agreement to enter into a joint venture with Shenyang Sunshine Pharmaceutical Company Ltd (3SBio) to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's C
Slide 18: Recent News
Recent News 2016 Strategic Accomplishments Moving Sorrento Forward • Validation of core technology with Servier license • Potential development and commercial milestones total nearly $1 billion • Moving pain management franchise forward with internal investments and acquisitions • cGMP manufacturing
Slide 19: Financial Summary
Financial Summary Recent Items of Financial Significance • Completed $150 million PIPE capital funding • Received $27.5 million from Servier up-front license fee • Completed stock swap transaction with NantKwest shares • Swapped SRNE shares with NK shares (marketable securities) plus $15.6 million c
Slide 20: Conclusion: Sorrento Therapeutics - OnTarget
Conclusion: Sorrento Therapeutics - OnTarget A Comprehensive Immunotherapy Company with Valuable Technologies and Assets • Recognized leader in therapeutic antibody technologies and discoveries • Comprehensive portfolio of novel immunotherapy technologies and product candidates • Clinical-stage bios
Slide 21: Contact
Therapeutics Contact Contact Henry Ji, PhD - President and CEO Kevin Herde - EVP and CFO hji@sorrentotherapeutics.com kherde@sorrentotherapeutics.com (858) 668-6923 (858) 210-3736 (c) 2016 Sorrento Therapeutics, Inc. All Rights Reserved. 21
Sorrento Therapeutics — Investor Presentation (September 2016) on 6ix